PUBLICATION
Monitoring antiangiogenesis of bevacizumab in zebrafish
- Authors
- Zhang, J., Gao, B., Zhang, W., Qian, Z., Xiang, Y.
- ID
- ZDB-PUB-180821-4
- Date
- 2018
- Source
- Drug design, development and therapy 12: 2423-2430 (Journal)
- Registered Authors
- Keywords
- VEGF, anti-angiogenesis, bevacizumab, subintestinal vein, zebrafish
- MeSH Terms
-
- Angiogenesis Inhibitors/pharmacology*
- Animals
- Bevacizumab/pharmacology*
- Dose-Response Relationship, Drug
- Vascular Endothelial Growth Factor A/antagonists & inhibitors*
- Zebrafish
- PubMed
- 30122900 Full text @ Drug Des Devel Ther
Citation
Zhang, J., Gao, B., Zhang, W., Qian, Z., Xiang, Y. (2018) Monitoring antiangiogenesis of bevacizumab in zebrafish. Drug design, development and therapy. 12:2423-2430.
Abstract
Bevacizumab, which is a humanized anti-VEGF antibody, has been successfully applied in clinics since 2004. Bevacizumab in combination with chemotherapy showed high safety and has been applied to solid tumors. However, studies on the insight into the mechanism about the antiangiogenesis activity of bevacizumab were mostly done on mice models, and so there are no visual and intuitive models to observe the process of antiangiogenesis. Here, we first used a zebrafish model to investigate the angiogenesis suppressing behavior of bevacizumab. Our results showed that bevacizumab inhibited formation of zebrafish subintestinal veins, which mimics the process of tumor angiogenesis in vivo. Meanwhile, bevacizumab caused specific vasculature formation defects in subintestinal veins but not in the trunk. Our study also indicated that bevacizumab could inhibit zebrafish retinal angiogenesis with therapeutic potential.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping